AccufyDx specializes in advanced technologies for the detection of measurable residual disease (MRD) through next-generation sequencing (NGS) on liquid biopsy samples. Their proprietary NGS tagging library preparation technology enhances the efficiency of tagging circulating tumor DNA (ctDNA) molecules, utilizing unique molecular barcodes that significantly improve the sensitivity and specificity of MRD detection. This method allows for a higher ratio of tagged DNA molecules, which is crucial for accurately identifying rare mutations and minimizing sequencing errors. Additionally, AccufyDx's NGS target enrichment technology selectively enriches target DNA molecules while preserving both genetic and epigenetic information, addressing the limitations of traditional methods like PCR and hybrid capture.

The combination of these technologies enables rapid sample preparation, with processes that can be completed in as little as four hours, while achieving a remarkable sensitivity of 0.001% variant allele frequency (VAF) or better. This advancement not only enhances the detection capabilities for various tumor types but also supports multiomic analyses, allowing for a comprehensive understanding of the molecular landscape of cancer. By integrating these innovative approaches, AccufyDx aims to improve patient outcomes through earlier and more accurate cancer detection, ultimately contributing to better treatment strategies and enhanced quality of life for patients.

United States

The Accufy NGS tagging library preparation and Accufy NGS target enrichment technologies revolutionize the MRD analysis on liquid biopsy samples via NGS in that they features the greatest sensitivity, short sample prep time and preservation of both epigenetic and genetic information from the patient DNA molecules.

AccufyDx

Company Details